English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met. Data as of 03/10/2026.
- ✅ Price trend passed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ✅ Correction passed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2024 → 2025: 61.07%
Price change 2025 → 2026: -0.80%
Price change 2026 (year to date): 0.44%
Financial growth
Revenue CAGR (5 years): 11.29%
Earnings CAGR (5 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.34
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 54.93
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 13.46% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="GALD.SW" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Galderma Group N | 66.0 | 0.34 | +8.4 % | 🔒 |
| Heineken N.V. | 19.5 | 1.14 | +3.9 % | – |
| Danone S.A. | 21.6 | 0.89 | +3.2 % | – |
| Ambev S.A. | 14.8 | 0.06 | +8.7 % | – |
| Kimberly-Clark Corporation | 14.5 | 4.86 | −0.9 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Galderma Group AG over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2021 | 3.8 bn | -172 m | -4.5 % | n/a |
| 2022 | 4.4 bn | -115 m | -2.6 % | +15.0 % |
| 2023 | 4.5 bn | -58.6 m | -1.3 % | +2.1 % |
| 2024 | 5.4 bn | 282 m | 5.2 % | +21.0 % |
| 2025 | 5.2 bn | 642 m | 12.2 % | -3.1 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Galderma Group AG over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 286 m | 234 m | 362 m | 457 m | 780 m |
| Total Debt | 5.7 bn | 5.7 bn | 4.8 bn | 2.8 bn | 2.8 bn |
| Net Debt | 5.4 bn | 5.4 bn | 4.5 bn | 2.3 bn | 2.0 bn |
| Equity | 4.5 bn | 4.5 bn | 5.3 bn | 7.8 bn | 8.2 bn |
| Total assets | 12.5 bn | 12.4 bn | 12.3 bn | 12.6 bn | 13.4 bn |
| Operating cash flow | 196 m | 115 m | 165 m | 430 m | 1.2 bn |
| Investments (capex) | 128 m | 172 m | 119 m | 275 m | 154 m |
| Free cash-flow | 67.7 m | -49.8 m | 43.3 m | 213 m | 1.0 bn |
| Share buybacks | 0 | 0 | 0 | 13.2 m | 363 m |
| Dividends paid | 0 | 0 | 0 | 0 | 41.0 m |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Galderma Group AG compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Galderma Group AG | 54.6 bn | 66.0 | 12.2 % |
| Beiersdorf AG BEI.DE | 20.2 bn | 18.9 | 9.5 % |
| e.l.f. Beauty, Inc. ELF | 6.6 bn | 28.0 | 8.5 % |
| The Estée Lauder Companies Inc. EL | 39.6 bn | 49.4 | -7.9 % |
| Puig Brands S.A. PUIG.MC | 12.1 bn | 18.7 | 25.3 % |
| The Procter & Gamble Company PG | 374 bn | 23.3 | 18.9 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Galderma Group AG publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 6.6 bn | 1.1 bn | 4.98 (4.44 / 5.24) | 38.7 | 10 |
| 2027 | 7.9 bn | 1.6 bn | 6.80 (6.47 / 7.18) | 28.4 | 13 |
| 2028 | 9.1 bn | 2.0 bn | 8.82 (7.29 / 9.99) | 21.9 | 8 |
Amounts in CHF, the reporting currency.
Track record against expectations: reported EPS above consensus 4 times over the last 6 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Galderma Group AG: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (CHF), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 24/04/2026 | 0.350 CHF | 28/04/2026 |
| 25/04/2025 | 0.150 CHF | 29/04/2025 |
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 23/07/2026 | 2.34 | 1.82 | +28.6 % |
| 05/03/2026 | 2.03 | 1.57 | +29.3 % |
| 24/07/2025 | 1.39 | 1.16 | +19.8 % |
| 06/03/2025 | 1.20 | 0.89 | +34.8 % |
| 24/10/2024 | 0.11 | 0.90 | -87.6 % |
| 25/07/2024 | 0.55 | 1.12 | -50.9 % |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Galderma Group AG.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 01/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Galderma Group AG
What is the Galderma Group AG share price?
Latest recorded price: 191.75 CHF on 06/11/2026, for a market cap of 54.5 bn USD.
What is the revenue of Galderma Group AG?
5.2 bn USD for fiscal year 2025, with net income of 642 m USD (net margin 12.2 %).
Does Galderma Group AG pay a dividend?
Yes. Latest dividend: 0.350 CHF per share, ex-dividend on 24/04/2026. Over 12 months: 0.350 CHF.
When does Galderma Group AG report its next earnings?
The next release is expected on 11/03/2027. EPS expected by analysts: 2.12.
What do analysts say about Galderma Group AG?
Out of 19 analysts: 15 buy or strong buy, 2 hold, 2 sell or strong sell.
What is the P/E ratio of Galderma Group AG?
Trailing 12-month P/E of 65.6.
Is Galderma Group AG stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN CH1335392721).
How many employees does Galderma Group AG have?
6,545 full-time employees according to the latest published profile.
Who runs Galderma Group AG?
Flemming Ornskov is the company's chief executive.